Cargando…

Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment

BACKGROUND: In Human African Trypanosomiasis, neurological symptoms dominate and cardiac involvement has been suggested. Because of increasing resistance to the available drugs for HAT, new compounds are desperately needed. Evaluation of cardiotoxicity is one parameter of drug safety, but without kn...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Johannes A., Schmid, Caecilia, Burri, Christian, Hatz, Christoph, Olson, Carol, Fungula, Blaise, Kazumba, Leon, Mangoni, Patrick, Mbo, Florent, Deo, Kambau, Mpanya, Alain, Dala, Amadeo, Franco, Jose R., Pohlig, Gabriele, Zellweger, Michael J.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640099/
https://www.ncbi.nlm.nih.gov/pubmed/19221604
http://dx.doi.org/10.1371/journal.pntd.0000383
_version_ 1782164523124260864
author Blum, Johannes A.
Schmid, Caecilia
Burri, Christian
Hatz, Christoph
Olson, Carol
Fungula, Blaise
Kazumba, Leon
Mangoni, Patrick
Mbo, Florent
Deo, Kambau
Mpanya, Alain
Dala, Amadeo
Franco, Jose R.
Pohlig, Gabriele
Zellweger, Michael J.
author_facet Blum, Johannes A.
Schmid, Caecilia
Burri, Christian
Hatz, Christoph
Olson, Carol
Fungula, Blaise
Kazumba, Leon
Mangoni, Patrick
Mbo, Florent
Deo, Kambau
Mpanya, Alain
Dala, Amadeo
Franco, Jose R.
Pohlig, Gabriele
Zellweger, Michael J.
author_sort Blum, Johannes A.
collection PubMed
description BACKGROUND: In Human African Trypanosomiasis, neurological symptoms dominate and cardiac involvement has been suggested. Because of increasing resistance to the available drugs for HAT, new compounds are desperately needed. Evaluation of cardiotoxicity is one parameter of drug safety, but without knowledge of the baseline heart involvement in HAT, cardiologic findings and drug-induced alterations will be difficult to interpret. The aims of the study were to assess the frequency and characteristics of electrocardiographic findings in the first stage of HAT, to compare these findings to those of second stage patients and healthy controls and to assess any potential effects of different therapeutic antiparasitic compounds with respect to ECG changes after treatment. METHODS: Four hundred and six patients with first stage HAT were recruited in the Democratic Republic of Congo, Angola and Sudan between 2002 and 2007 in a series of clinical trials comparing the efficacy and safety of the experimental treatment DB289 to the standard first stage treatment, pentamidine. These ECGs were compared to the ECGs of healthy volunteers (n = 61) and to those of second stage HAT patients (n = 56). RESULTS: In first and second stage HAT, a prolonged QTc interval, repolarization changes and low voltage were significantly more frequent than in healthy controls. Treatment in first stage was associated with repolarization changes in both the DB289 and the pentamidine group to a similar extent. The QTc interval did not change during treatment. CONCLUSIONS: Cardiac involvement in HAT, as demonstrated by ECG alterations, appears early in the evolution of the disease. The prolongation of the QTC interval comprises a risk of fatal arrhythmias if new drugs with an additional potential of QTC prolongation will be used. During treatment ECG abnormalities such as repolarization changes consistent with peri-myocarditis occur frequently and appear to be associated with the disease stage, but not with a specific drug.
format Text
id pubmed-2640099
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-26400992009-02-17 Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment Blum, Johannes A. Schmid, Caecilia Burri, Christian Hatz, Christoph Olson, Carol Fungula, Blaise Kazumba, Leon Mangoni, Patrick Mbo, Florent Deo, Kambau Mpanya, Alain Dala, Amadeo Franco, Jose R. Pohlig, Gabriele Zellweger, Michael J. PLoS Negl Trop Dis Research Article BACKGROUND: In Human African Trypanosomiasis, neurological symptoms dominate and cardiac involvement has been suggested. Because of increasing resistance to the available drugs for HAT, new compounds are desperately needed. Evaluation of cardiotoxicity is one parameter of drug safety, but without knowledge of the baseline heart involvement in HAT, cardiologic findings and drug-induced alterations will be difficult to interpret. The aims of the study were to assess the frequency and characteristics of electrocardiographic findings in the first stage of HAT, to compare these findings to those of second stage patients and healthy controls and to assess any potential effects of different therapeutic antiparasitic compounds with respect to ECG changes after treatment. METHODS: Four hundred and six patients with first stage HAT were recruited in the Democratic Republic of Congo, Angola and Sudan between 2002 and 2007 in a series of clinical trials comparing the efficacy and safety of the experimental treatment DB289 to the standard first stage treatment, pentamidine. These ECGs were compared to the ECGs of healthy volunteers (n = 61) and to those of second stage HAT patients (n = 56). RESULTS: In first and second stage HAT, a prolonged QTc interval, repolarization changes and low voltage were significantly more frequent than in healthy controls. Treatment in first stage was associated with repolarization changes in both the DB289 and the pentamidine group to a similar extent. The QTc interval did not change during treatment. CONCLUSIONS: Cardiac involvement in HAT, as demonstrated by ECG alterations, appears early in the evolution of the disease. The prolongation of the QTC interval comprises a risk of fatal arrhythmias if new drugs with an additional potential of QTC prolongation will be used. During treatment ECG abnormalities such as repolarization changes consistent with peri-myocarditis occur frequently and appear to be associated with the disease stage, but not with a specific drug. Public Library of Science 2009-02-17 /pmc/articles/PMC2640099/ /pubmed/19221604 http://dx.doi.org/10.1371/journal.pntd.0000383 Text en Blum et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Blum, Johannes A.
Schmid, Caecilia
Burri, Christian
Hatz, Christoph
Olson, Carol
Fungula, Blaise
Kazumba, Leon
Mangoni, Patrick
Mbo, Florent
Deo, Kambau
Mpanya, Alain
Dala, Amadeo
Franco, Jose R.
Pohlig, Gabriele
Zellweger, Michael J.
Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment
title Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment
title_full Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment
title_fullStr Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment
title_full_unstemmed Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment
title_short Cardiac Alterations in Human African Trypanosomiasis (T.b. gambiense) with Respect to the Disease Stage and Antiparasitic Treatment
title_sort cardiac alterations in human african trypanosomiasis (t.b. gambiense) with respect to the disease stage and antiparasitic treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2640099/
https://www.ncbi.nlm.nih.gov/pubmed/19221604
http://dx.doi.org/10.1371/journal.pntd.0000383
work_keys_str_mv AT blumjohannesa cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT schmidcaecilia cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT burrichristian cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT hatzchristoph cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT olsoncarol cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT fungulablaise cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT kazumbaleon cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT mangonipatrick cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT mboflorent cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT deokambau cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT mpanyaalain cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT dalaamadeo cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT francojoser cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT pohliggabriele cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment
AT zellwegermichaelj cardiacalterationsinhumanafricantrypanosomiasistbgambiensewithrespecttothediseasestageandantiparasitictreatment